Open AccessPD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
Author(s) -
Belén Rubio-Viqueira,
M. Majem Tarruella,
M. Lázaro,
S. Vázquez Estévez,
Juan Felipe Córdoba-Ortega,
I. Maestu Maiques,
Jorge García González,
A. Blasco Cordellat,
Javier Valdivia-Bautista,
Carmen González Arenas,
J. Torres
Publication year - 2021
Publication title -
lung cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1974
pISSN - 1758-1966
DOI - 10.2217/lmt-2021-0008
Subject(s) - medicine , lung cancer , immunotherapy , oncology , clinical trial , stage (stratigraphy) , chemotherapy , clinical practice , pd l1 , disease , retrospective cohort study , cancer , physical therapy , paleontology , biology
Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods: Multicenter, retrospective study. Results: Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1. Conclusion: PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.